Drug Type Small molecule drug, Liposomal Drug |
Synonyms NDLS, DoceAqualip |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors, Cells inhibitors, Mitosis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date India (01 Jan 2013), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Gastric Adenocarcinoma | India | 01 Jan 2013 | |
Breast Cancer | India | 01 Jan 2013 | |
Castration-Resistant Prostatic Cancer | India | 01 Jan 2013 | |
Non-Small Cell Lung Cancer | India | 01 Jan 2013 | |
Squamous Cell Carcinoma of Head and Neck | India | 01 Jan 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally advanced breast cancer | Phase 3 | United States | 10 Jul 2018 | |
Locally advanced breast cancer | Phase 3 | India | 10 Jul 2018 | |
Triple Negative Breast Cancer | Phase 3 | United States | 10 Jul 2018 | |
Triple Negative Breast Cancer | Phase 3 | India | 10 Jul 2018 |
Phase 4 | Metastatic castration-resistant prostate cancer Prostate specific antigen | 86 | Nanosomal docetaxel lipid suspension (NDLS) 75 mg/m2 | qkzqnetwch(dghkdxcpqf) = ivohrojadu zcsvlyjgir (txkggsvapo, 9.31 - 27.14) View more | Positive | 13 Feb 2025 | |
Phase 3 | Squamous Cell Carcinoma of Head and Neck Neoadjuvant | 495 | oprlcpoain(qpidsudwyk) = Use of NDLS led to a significant decrease in the incidence of mucositis mfmsivntfl (skgbnivpzy ) View more | - | 22 Oct 2023 | ||